Global Multiple Sclerosis Drugs Market Size study & Forecast, by Drug Class (Immunomodulators, Immunosuppressants, Interferons) by Route of Administration (Oral, Injection), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and

Global Multiple Sclerosis Drugs Market Size study & Forecast, by Drug Class (Immunomodulators, Immunosuppressants, Interferons) by Route of Administration (Oral, Injection), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Regional Analysis, 2022-2029

Global Multiple Sclerosis Drugs Market is valued approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XXX% over the forecast period 2022-2029. Multiple sclerosis is an inflammatory immune-mediated disorder that affects nerve cells in the brain and the spinal cord, causing axonal transection, demyelination, and neurodegeneration. Some of the most often used treatments include physical therapy, muscle relaxants, antidepressants, and oral, injectable, and infused medications. Oral drugs including dimethyl fumarate, teriflunomide, and cladribine; intravenous infusion therapies like ocrelizumab; and injectable therapies like interferon-beta, glatiramer acetate, given intramuscularly or subcutaneously. The key factor driving the market growth is rising prevalence of Multiple Sclerosis disease and rising R&D investment by the market players for the drugs development that anticipated to support the market growth during forecast period.

According to the Multiple Sclerosis International Federation (MSIF), the number of patients with multiple sclerosis throughout the globe increased from 2.3 million in 2013 to 2.8 million in 2020. The demand for effective multiple sclerosis diagnosis and treatment has increased worldwide as a result of the disease's rising prevalence. Also, the rising R&D and clinical trial by the market players will create the lucrative demand for the market. For instance, For the therapy of non-relapsing secondary progressive MS (nrSPMS), relapsing forms of MS (RMS), and primary progressive MS, Sanofi is conducting a phase III clinical trial for tolebrutinib (PPMS). Sanofi anticipates submitting this medication in 2024 and 2025+, respectively, for the approved indications. Additionally, the rising government support for the treatment of multiple sclerosis is likely to increase the market growth during the forecast period. However, the high cost of Multiple Sclerosis Drugs stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Multiple Sclerosis Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the rising R&D investment, new product development, and growing demand for immunosuppressant and molecular antibody drugs. Whereas, Asia Pacific is also anticipated to exhibit highest growth rate over the forecast period, owing to factors such as growing prevalence of multiple sclerosis disease and rising government initiatives in several countries to reduce the cost of treatment would create lucrative growth prospects for the Multiple Sclerosis Drugs market across Asia Pacific region.

Major market player included in this report are:
Biogen Inc.
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
Merck & Co., Inc.
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
Bristol-Myers Squibb Company
Cipla Inc.

Recent Developments in the Market:
 In March 2021, Janssen Pharmaceutical, Inc. revealed the U.S. FDA approval of Ponvory, an oral specific sphingosine-1-phosphate receptor 1 (S1P1) modulator to treat people with relapsing forms of MS. In comparison to Aubagio, Ponvory is more effective at lowering annual relapse rates. The company increased its range of products for the treatment of MS with the inclusion of this product in its portfolio.

Global Multiple Sclerosis Drugs Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Drug Class, Route of Administration, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Drug Class:
Immunomodulators
Immunosuppressants
Interferons

By Route of Administration:
Oral
Injection

By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Biogen Inc.
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
Merck & Co., Inc.
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
Bristol-Myers Squibb Company
Cipla Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.